{
    "root": "b73e1972-e96d-4463-ad39-f7bed99466e9",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "Human Prescription Drug Label",
    "name": {
        "text": "LURASIDONE HYDROCHLORIDE"
    },
    "value": "20250306",
    "ingredients": [
        {
            "name": "LURASIDONE HYDROCHLORIDE",
            "code": "O0P4I5851I"
        },
        {
            "name": "CROSPOVIDONE (120 .MU.M)",
            "code": "68401960MK"
        },
        {
            "name": "HYDROXYPROPYL CELLULOSE (20000 WAMW)",
            "code": "KZQ570MOA5"
        },
        {
            "name": "HYPROMELLOSE 2910 (6 MPA.S)",
            "code": "0WZ8WG20P6"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "MANNITOL",
            "code": "3OWL53L36A"
        },
        {
            "name": "POLYETHYLENE GLYCOL 6000",
            "code": "30IQX730WE"
        },
        {
            "name": "STARCH, CORN",
            "code": "O8232NY3SJ"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "FD&C BLUE NO. 2",
            "code": "L06K8R7DQK"
        },
        {
            "name": "FERRIC OXIDE YELLOW",
            "code": "EX438O2MRT"
        }
    ],
    "indications": "Lurasidone hydrochloride tablets are indicated for:\n                  \n                     Treatment of adult and adolescent patients (13 to 17 years) with schizophrenia [see Clinical Studies (14.1)].\n                     \n                     Monotherapy treatment of adult and pediatric patients (10 to 17 years) with major depressive episode associated with bipolar I disorder (bipolar depression) [see Clinical Studies (14.2)].\n                     \n                     Adjunctive treatment with lithium or valproate in adult patients with major depressive episode associated with bipolar I disorder (bipolar depression) [see Clinical Studies (14.2)].",
    "contraindications": "Lurasidone hydrochloride tablets should be taken with food (at least 350 calories). Administration with food substantially increases the absorption of lurasidone hydrochloride tablets (2.3, 12.3). Indication Starting Dose Recommended Dose Schizophrenia – adults ( 2.1 ) 40 mg per day 40 mg to 160 mg per day Schizophrenia – adolescents (13 to 17 years) ( 2.1 ) 40 mg per day 40 mg to 80 mg per day Bipolar Depression – adults ( 2.2 ) 20 mg per day 20 mg to 120 mg per day Bipolar Depression – pediatric patients (10 to 17 years) ( 2.2 ) 20 mg per day 20 mg to 80 mg per day Moderate and Severe Renal Impairment: Recommended starting dose is 20 mg per day, and the maximum recommended dose is 80 mg per day ( 2.4 , 8.6 ). Moderate and Severe Hepatic Impairment: Recommended starting dose is 20 mg per day. The maximum recommended dose is 80 mg per day in moderate hepatic impairment and 40 mg per day in severe hepatic impairment ( 2.5 , 8.7 ). Concomitant Use of a Moderate CYP3A4 inhibitor (e.g., diltiazem): Lurasidone hydrochloride tablets dose should be reduced to half of the original dose level. Recommended starting dose is 20 mg per day. Maximum recommended dose is 80 mg per day ( 2.6 , 7.1 ). Concomitant Use of a Moderate CYP3A4 Inducer: It may be necessary to increase the dose of lurasidone hydrochloride tablets ( 2.6 , 7.1 ).",
    "warningsAndPrecautions": "Lurasidone Hydrochloride Tablets 20 mg are white to off-white, round shaped, biconvex, film-coated tablets debossed with “L” on one side and “25” on other side.\n                                          Bottles of 30     NDC 65862-953-30                    Bottles of 90     NDC 65862-953-90                    Bottles of 500   NDC 65862-953-05\n                     \n                         Lurasidone Hydrochloride Tablets 40 mg are white to off-white, round shaped, biconvex, film-coated tablets debossed with “L” on one side and “26” on other side.\n                                         Bottles of 30     NDC 65862-954-30                    Bottles of 90     NDC 65862-954-90                    Bottles of 500   NDC 65862-954-05\n                     \n                         Lurasidone Hydrochloride Tablets 60 mg are white to off-white, oblong shaped, biconvex, film-coated tablets debossed with “L” on one side and “10” on other side.\n                                          Bottles of 30     NDC 65862-955-30                    Bottles of 90     NDC 65862-955-90                    Bottles of 500   NDC 65862-955-05\n                     \n                         Lurasidone Hydrochloride Tablets 80 mg are pale green to green color, oval shaped, biconvex, film-coated tablets debossed with “L” on one side and “27” on other side.\n                                          Bottles of 30     NDC 65862-956-30                    Bottles of 90     NDC 65862-956-90                    Bottles of 500   NDC 65862-956-05\n                     \n                         Lurasidone Hydrochloride Tablets 120 mg are white to off-white, oval shaped, biconvex, film-coated tablets debossed with “L” on one side and “29” on other side.\n                                          Bottles of 30     NDC 65862-957-30                    Bottles of 90     NDC 65862-957-90                    Bottles of 500   NDC 65862-957-05\n                     \n                        \n                            Storage\n                        \n                     \n                      Store lurasidone hydrochloride tablets at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature].",
    "adverseReactions": "Known hypersensitivity to lurasidone hydrochloride or any components in the formulation. Angioedema has been observed with lurasidone [see Adverse Reactions (6.1)].\n                     Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin, ritonavir, voriconazole, mibefradil, etc.) [see Drug Interactions (7.1)].  \n                     \n                     Strong CYP3A4 inducers (e.g., rifampin, avasimibe, St. John’s wort, phenytoin, carbamazepine, etc.) [see Drug Interactions (7.1)]."
}